Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amgen Inc AMGN

Healthcare Biotechnology
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL... see more

Recent & Breaking News (NDAQ:AMGN)

AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

PR Newswire February 9, 2024

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS

PR Newswire February 6, 2024

AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

PR Newswire February 1, 2024

deCODE genetics: A sequence variant that increases risk of pregnancy loss

PR Newswire January 29, 2024

AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

PR Newswire January 3, 2024

AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)

PR Newswire December 26, 2023

AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION

PR Newswire December 14, 2023

AMGEN TO SPONSOR THE IRISH OPEN

PR Newswire December 14, 2023

FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer

PR Newswire December 13, 2023

AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE

PR Newswire December 12, 2023

AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023

PR Newswire December 8, 2023

AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE

PR Newswire November 22, 2023

AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023

PR Newswire November 10, 2023

AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023

PR Newswire November 7, 2023

AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023

PR Newswire November 7, 2023

AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)

PR Newswire November 2, 2023

AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO

PR Newswire November 1, 2023

AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS

PR Newswire October 31, 2023

AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS

PR Newswire October 25, 2023

AMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND

PR Newswire October 24, 2023